Moxifloxacin 1 A Pharma

Moxifloxacin, the active ingredient in Moxifloxacin 1 A Pharma, is a fluoroquinolone presented as an oral tablet for oral use. It treats a range of bacterial infections, including community‑acquired pneumonia, acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and skin and skin structure infections in adult patients.

GNH USA supplies Moxifloxacin 1 A Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for importers.

Moxifloxacin is indicated for several bacterial infections affecting the respiratory tract and skin.

Community‑acquired pneumonia: eradicates the causative pathogens, leading to clinical improvement and resolution of pulmonary infiltrates. Acute bacterial sinusitis: reduces sinus mucosal inflammation by eliminating the infecting organisms, relieving congestion and facial pain. Acute bacterial exacerbation of chronic bronchitis: controls bacterial overgrowth, decreasing sputum production and improving airflow. Skin and skin structure infections: achieves bacterial clearance in cellulitis, abscesses and wound infections, promoting healing. Other susceptible bacterial infections: may be used based on microbiological susceptibility, providing a broad‑spectrum option.

Moxifloxacin may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset that may be transient. - Diarrhea: loose stools that can range from mild to watery. - Headache: dull or throbbing pain often relieved with rest. - Dizziness: sensation of light‑headedness, especially when standing quickly.

Serious or Rare Side Effects: - Tendon rupture: sudden tendon pain or rupture, most often in the Achilles. - QT interval prolongation: cardiac electrical changes that can predispose to arrhythmias. - Severe allergic reactions: including rash, swelling, bronchospasm, or anaphylaxis. - Clostridioides difficile‑associated diarrhea: severe colitis presenting with watery, foul‑smelling stools.

When prescribing Moxifloxacin, clinicians should observe several precautionary measures to minimise risk.

- Assess renal function: adjust use in patients with impaired clearance. - Monitor cardiac status: avoid in patients with known QT prolongation. - Avoid in hypersensitivity: discontinue if allergic reactions develop. - Use cautiously in the elderly: increased susceptibility to tendon injury. - Review concomitant medications: limit use with drugs that also prolong QT. - Store at room temperature: keep in the original container, protect from moisture and light.

Moxifloxacin interacts with several medicines; awareness of major and moderate interactions helps ensure safe therapy.

Major Interactions (Avoid): - Antacids containing magnesium or aluminum: markedly reduce oral absorption of the drug. - Systemic corticosteroids: increase risk of tendon rupture when combined. - Warfarin: may enhance anticoagulant effect, raising bleeding risk. - Other fluoroquinolones: additive toxicity; concurrent use is not recommended.

Moderate Interactions (Monitor Closely): - QT‑prolonging agents (e.g., macrolides, antiarrhythmics): may exacerbate cardiac rhythm disturbances. - Theophylline: Moxifloxacin can raise plasma levels, requiring dose adjustment. - NSAIDs: may increase risk of central nervous system side effects.